Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78947 | 1.00 | LMNA (0.48) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL475421 | 1.00 | LMNA (0.48) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| Methylene Chloride SCHEMBL28127319 | 0.93 | LMNA (0.47) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| Methylene Chloride SCHEMBL28127317 | 0.93 | LMNA (0.47) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4939720 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL4939718 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL5026447 | 0.89 | KMT2A (0.42) | LMNAGAAKMT2APOLBCNR1 | |
| SCHEMBL2790715 | 0.87 | LMNA (0.43) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL30948745 | 0.87 | LMNA (0.45) | LMNAGAAKMT2APOLBSMN1; SMN2 | |
| SCHEMBL6810038 | 0.87 | KMT2A (0.41) | LMNAGAAKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | claimed |
| WO-2025073270-A1 | BIPHENYL TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 海南因瑞生物医药科技有限公司 | 2025-04-10 | — | — | WO | claimed |
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | claimed |
| CN-117957223-A | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117327000-A | Biphenyl tetrahydropyrrole compound and preparation method and application thereof | 海南因瑞生物医药科技有限公司 | 2024-01-02 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-114763356-B | Pyrrolo-benzodiazepine compound, and preparation method and application thereof | 沈阳药科大学 | 2023-06-20 | — | — | CN | claimed |
| WO-2023036821-A1 | NEW QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-16 | — | — | WO | claimed |
| EP-4148052-A1 | NEW QUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-114763356-A | Pyrrolobenzodiazepine compounds, and preparation method and application thereof | 沈阳药科大学 | 2022-07-19 | — | — | CN | claimed |
| EP-0342055-B1 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1994-01-12 | — | — | EP | claimed |
| EP-0342054-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1993-11-03 | — | — | EP | claimed |
| EP-0594608-A4 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. | RES CORP TECHNOLOGIES INC (US) | 1993-03-15 | — | — | EP | claimed |
| US-5137714-A | Anhydrous cosmetic composition comprising stable lower alkyl esters of pyroglutamic acid | UNILEVER PATENT HOLDINGS B.V. (NL) | 1992-08-11 | — | — | US | claimed |
| WO-1991014672-A1 | CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-10-03 | — | — | WO | claimed |
| US-4912232-A | Preparation of N-hydrocarbylcarbonyl-5-(1-hydrocarbylcarbonyloxy)hydrocarbyl-pyrrolidin-2-one | DOW CHEMICAL COMPANY (US) | 1990-03-27 | — | — | US | claimed |
| EP-0342056-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342055-A2 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0342054-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | claimed |
| EP-0277428-A2 | Cosmetic composition | UNILEVER PLC (GB) | 1988-08-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | LMNA 1309/4885GAA 1046/4885KMT2A 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.